CVS Health has announced plans to split into two publicly traded companies by the first half of 2028, separating its pharmacy business, including roughly 9,000 retail locations, from its insurance business and pharmacy benefit manager, Caremark. The move comes more than two years after the company considered a breakup and walked away from it. The reason it now looks viable is simple: the business has become more stable, and the company says it is acting out of strength rather than distress.

The case for the separation rests on numbers the report provides. CEO David Joyner said that in 2024 the company was "in a turnaround" without the flexibility or cash to execute a split. CVS has since posted eight consecutive quarters of beating Wall Street earnings estimates, and it expects at least $15.5 billion in operating cash flow in 2026, up from $9.1 billion in 2024. Analysts such as Michael Cherny of Leerink Partners describe the retail pharmacy as a much different business than it was a decade ago. A unit that once could not overcome its headwinds now appears able to stand alone.

Still, the report is clear that retail pharmacy is not a growth engine. Its adjusted operating margins sit at roughly 4% to 5%, and investors value it at a discount. That is precisely why the split should be judged on transparency rather than on hope. If the pharmacy is valued low, separating it may reveal the earnings of Aetna and Caremark more clearly, as RBC's Ben Hendrix argues. Investors should welcome that clarity, but they should also ask whether the new pharmacy company can carry its own debt and costs without the insurance and PBM businesses that once shored it up.

The regulatory backdrop deserves more weight than Joyner's denial suggests. The report notes that Tennessee and Arkansas have passed laws barring one company from owning both a pharmacy and a PBM, that the Arkansas measure has been held up in court, and that Cherny questions whether the combined structure had become too tenuous. Joyner has told the Wall Street Journal the split is not about regulation. Even if that is true, the company should expect regulators and lawmakers to read it as an admission about how hard integration has become to defend.

The stock's roughly 12% drop on announcement day suggests the market has not yet accepted the story. My view is that the separation is the right call for a company that has finally earned the choice, but CVS should prove, through quarterly disclosure of the commercial dealings between the two new companies, that the breakup is about focus and not an escape from scrutiny.